VolitionRx Limited — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. Although the request metadata refers to 2015 Q4, this filing is an annual report and principally compares full-year 2015 with full-year 2014. Amounts are in U.S. dollars.
Business context
VolitionRx is a clinical-stage life sciences company developing blood-based diagnostic tests, primarily for cancer, using its Nucleosomics and NuQ assay platform. The company reported no revenue in either 2015 or 2014 and had no products available for sale in the clinical in-vitro diagnostic market. In 2015, it concentrated resources on clinical IVD products and deprioritized HyperGenomics work.
Financial performance and position
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $10.01 million | $5.95 million |
| Research and development expense | $6.10 million | $4.04 million |
| Net loss | $9.53 million | $8.21 million |
| Basic and diluted loss per share | $0.54 | $0.61 |
| Net cash used in operating activities | $8.77 million | $4.14 million |
| Cash at year-end | $5.92 million | $2.14 million |
| Current assets | $6.22 million | $2.34 million |
| Current liabilities | $1.12 million | $2.71 million |
| Total liabilities | $1.67 million | $3.06 million |
2015 working capital was a surplus of $5.10 million. The company reported no product gross margin; revenue and gross margin are not meaningful while sales remain zero. Net other income was $470,873, including a $339,744 gain from remeasurement of derivative liabilities and $146,812 in grants. The comparable 2014 period had $2.26 million of net other expense, including a $2.42 million derivative remeasurement loss.
Net cash used in investing activities was $352,243, including $55,000 for a patent purchase. Financing activities provided $12.88 million, mainly from equity issuance and warrant and option exercises. The February 2015 public offering generated approximately $9.7 million in net proceeds, and the company also raised approximately $1.5 million in a private placement. Year-end capital lease liabilities were $381,201 in total, of which $81,338 was current; the company reported no derivative liability at year-end. No significant off-balance-sheet arrangements were disclosed.
Material changes versus 2014
- Operating expenses increased 68% to $10.01 million; R&D rose 51% to $6.10 million, primarily reflecting higher antibody and sample costs and the Hvidovre study.
- Net loss increased 16% to $9.53 million, while loss per share improved from $0.61 to $0.54 as weighted-average shares outstanding rose 32% to 17.73 million.
- Operating cash use more than doubled. Equity financing helped lift year-end cash by $3.78 million, but the company remained reliant on external capital.
- Common shares outstanding increased from 14.69 million to 18.76 million during the year, reflecting financing and warrant exercises.
- The company obtained a CE Mark for one NuQ biomarker in September 2015 and purchased the patent underlying its NuQ-M tests.
Outlook, commentary, and risks
Management planned to seek additional CE Marks in 2016 and expected to pursue CE Marking for a symptomatic colorectal cancer panel in the second half of 2016. The company expected results from its prospective 14,000-participant colorectal screening study in late 2016. It planned U.S. trials for a 510(k) symptomatic adjunct application, targeting clearance in 2017, and a separate PMA pathway for screening; the filing estimated costs of $1 million–$1.5 million for the 510(k) process and approximately $5 million for PMA, while noting that PMA costs could ultimately be much higher. These are management plans, not assured outcomes.
Clinical findings disclosed included a four-assay panel that detected 91% of colorectal cancer cases at 90% specificity in a 121-patient study, and preliminary lung-study results reporting 93% detection with 91% specificity in the first 73 participants. These results are from limited studies and do not establish commercial performance. The filing also discussed pancreatic cancer findings from a small study. Further validation, regulatory clearance or approval, manufacturing, distribution, reimbursement, and market acceptance remain necessary.
The independent auditor expressed substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, accumulated deficit of $29.04 million, operating cash outflows, and no revenue. Management stated that continued operations depended on financing, grants, cost controls, and eventual profitable operations; inadequate funding could delay development or force the company to curtail or cease operations.
Management reported ineffective disclosure controls and material weaknesses in cash-process controls, including insufficient segregation of cash handling and accounting and lack of dual authorization on some bank accounts. Remediation was underway; the company stated that all company and subsidiary bank accounts had dual payment authorization by March 11, 2016. Other significant risks include clinical and regulatory failure or delay, additional funding needs and dilution, evolving U.S. LDT oversight, competition from better-resourced companies, dependence on third-party suppliers and distributors, and patent protection and enforcement. No material pending legal proceedings were reported.
Most important facts for investors to verify
- Cash burn and financing needs: assess the $5.92 million year-end cash balance against subsequent expenditures, fundraising, and development commitments.
- Clinical validation: verify full study results, cohort sizes, performance measures, and whether early findings hold in larger prospective populations.
- Regulatory progress: confirm CE Mark applications and status, U.S. trial initiation, and the timing, scope, and cost of FDA submissions.
- Commercial readiness: verify manufacturing capacity, distribution or licensing agreements, reimbursement prospects, and any revenue-generating product launch.
- Controls and dilution: monitor remediation of the disclosed material weaknesses, subsequent equity or debt financing, and changes in shares outstanding.
- Commitments and contingencies: review capital lease payments, Walloon Region grant repayment and potential royalty obligations, and clinical-study commitments.